Ask about the use as well as the product
As of September 2026, Medicare drug plans could cover these medicines for certain accepted uses other than weight loss, but each plan’s drug list and approval rules still applied.
Medicare guidance on coverage ↗- What would I pay for the medicine?
- Are the visits and tests covered separately?
- What happens if approval is refused?
- Does coverage need to be checked again later?
Medicare has a temporary route for some people
The Centers for Medicare & Medicaid Services, or CMS, oversees Medicare.
As of September 2026, CMS described a temporary program with a $50 monthly payment for eligible people, running from July 2026 through December 2027.
Medicare GLP-1 Bridge is the name of this temporary program.
For semaglutide, the Bridge includes semaglutide (Wegovy) injections and tablets for weight care; semaglutide (Ozempic) for weight care is not included, as of September 2026.
CMS describes the temporary program ↗The headline does not settle eligibility
Bridge eligibility depends on weight, health history and plan type, and requires a prescription and approval in advance, as of September 2026.
The Bridge excluded anyone with type 2 diabetes as of September 2026; their treatment used the ordinary Part D route.
A GLP-1 prescription, such as semaglutide, paid through Part D for you during 2026 meant you could not join the Bridge that year.
Ask your drug plan to check your prescription records against this rule, even if you take the medicine for another reason.
Money you paid under the Bridge did not count toward your yearly Part D limit for spending out of pocket, as of September 2026.
The Bridge offered no extra help to lower its $50 payment for people with low incomes, as of September 2026.
That included people who got help with ordinary Part D costs.
The full CMS eligibility rules ↗